Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
77,914.62
(
-1.45%
)
News Focus
News Focus
Post# of 257579
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: investorgold2002 post# 121523

Monday, 06/13/2011 12:53:21 AM

Monday, June 13, 2011 12:53:21 AM

Post# of 257579

MNTA—I am not sure I agree with your characterization of "legacy business" that Wheeler was talking about.

I’m very, very sure that legacy business in this context used on the GS webcast refers to prospective partners’ traditional branded biologics, not to their biosimilars.

If you don’t want to take my word for it, call MNTA and ask.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today